Search Results

Strategic Investments in the EU and US strengthen Vetter’s Global Footprint • Building permit application for German site submitted • Construction start is scheduled for the 2nd quarter 2026, with operational readiness in 2031 • Expansions in the US and Europe are included in a €1.5 billion investment plan

PCI Pharma Services (PCI), a leading global contract development and manufacturing organization (CDMO), today announced the closing of the previously announced acquisition of Lyophilization Services of New England, Inc. (LSNE), a premier contract development and manufacturing organization headquartered in Bedford, New Hampshire.

A new report by Bryter released today reveals where pharma can lead as patients turn to (and question) AI tools for mental health.

Only a handful of the top pharmas have signed Most Favored Nation drug pricing deals with the White House, while smaller biotechs continue to hang in limbo.

Pharmas will need to provide their latest stance on the Most Favored Nation drug pricing plans, while biotech finally gets a break after a few tough years.

Aldena Therapeutics has chosen PCI Pharma Services, a world-leading global contract development and manufacturing organization to formulate, package, and distribute ALD-102, an siRNA-based investigational injectable treatment for inflammatory dermatological conditions, all under one roof at PCI’s San Diego facility.

U.K.-based pharmas will not face tariffs as long as Donald Trump is president, according to the agreement.

Long a quieter, locally focused industry, Japanese pharma giants are increasingly looking to the rest of the world for deals.